Introduction
Episodic disorders are common in humans and represent a diverse and interesting group of diseases. These disorders seem, at first, largely disparate; movement disorders, cardiac arrhythmias, and migraines are typically not grouped together. With further examination, however, these disparate disorders are actually closely related in their biophysical underpinnings. Many channelopathies are simple Mendelian disorders, making them amenable to genetic mapping, though, as discussed below, this is not always the case.
A Variety of Phenotypes Affecting Different Cell Types
Ion channels are expressed broadly throughout the body. While there are a number of channelopathies, such as polycystic kidney disease, focal segmental glomerulosclerosis, and x-linked congenital stationary night blindness, that either affect nonexcitable cells or are nonepisodic in nature, this review focuses on the large number of episodic channelopathies of muscles and neurons.
Skeletal Muscle
The first delineated and most paradigmatic of the channelopathies are those resulting in primary skeletal muscle disorders. These disorders form a spectrum from muscle hyper-to hypoexcitability, with hyperexcitable muscle manifesting clinically as myotonia and hypoexcitability as weakness or paralysis. At the far hyperexcitable end of this spectrum is myotonia congenita. Myotonia congenita is also one of the few channelopathies with both dominant and recessive forms, Thomsen disease and Becker generalized myotonia, respectively (Koch et al., 1992; Lossin and George, 2008) . These patients complain of ''stiffness'' after resting for a period of time, and this improves with continued movement, which is referred to as the warm-up phenomenon.
Both hyperkalemic periodic paralysis (hyperKPP), the first characterized human channelopathy, and hypokalemic periodic paralysis (hypoKPP) result in weakness or paralysis. HyperKPP is thus named because attacks can be precipitated by administration of potassium. During attacks, serum potassium may be elevated but is often normal (Ptá cek et al., 1991; Rojas et al., 1991) . Regardless of the serum potassium level during an attack, potassium administration will uniformly induce a bout of weakness. These patients often have muscle hyperexcitability (myotonia) at rest or following activity. Monitoring a patient clinically or by electromyography (EMG) during the evolution of an attack shows that myotonia is present and diminishes as hyperexcitability transitions into inexcitability or paralysis. As hyperKPP patients age, some develop progressive fixed weakness (myopathy) in the affected limbs.
Not all skeletal muscle channelopathies lead to myotonia. HypoKPP patients show low serum potassium levels during bouts of weakness, and attacks can be induced by lowering serum potassium (e.g., by administering glucose and insulin, which drive potassium into muscle) (Bulman et al., 1999; JurkatRott et al., 1994; Ptá cek et al., 1994) . However, these patients never show myotonia. As with hyperKPP, some hypoKPP patients develop progressive fixed weakness in the affected limbs.
Another potassium-sensitive phenotype is potassium-aggravated myotonia (PAM). These patients have myotonia that is precipitated or worsened by administration of potassium, but these patients never develop episodic weakness. That is, the hyperexcitability never transitions into inexcitability.
Paramyotonia congenita (PMC) is similar to hyperKPP in that patients generally manifest signs of both hyperexcitability (myotonia) and inexcitability (episodic weakness) (Heine et al., 1993; McClatchey et al., 1992; Ptá cek et al., 1992) . However, attacks are not precipitated by administration of potassium. Rather, muscle cooling leads to prominent myotonia that often transitions to weakness. Unlike the warm-up phenomenon in myotonia congenita, myotonia in these patients often worsens with repeated muscle use. Thus, it is called paradoxical myotonia. PMC mutations represent one of the rare forms of temperature-sensitive mutations seen in humans.
Finally, rare families are reported in which a syndrome of myotonia/episodic weakness is seen but attacks can be precipitated by both potassium administration and muscle cooling. This appears to be a distinct but hybrid phenotype of hyperKPP/PMC (de Silva et al., 1990) . Neuromuscular Junction Abnormalities of muscle function can also arise at the level of the neuromuscular junction and include the congenital myasthenic syndromes (CMS). There are actually three categories of CMS, affecting (1) the presynaptic membrane (nerve), (2) the synaptic cleft, or (3) the postsynaptic membrane (muscle end plate). There are a wide range of clinically distinguishable varieties, each with a different molecular etiology (Engel et al., 2010) . All of these alterations result in altered synaptic processing. Peripheral Nerve Channelopathies are not restricted to disorders of muscle or neuromuscular junction. A triad of pain perception disorders have recently been described that can result in either absence of or hypersensitivity to painful stimuli (Fischer and Waxman, 2010) . Primary erythermelalgia is characterized by bouts of burning pain, flushing, and swelling of the feet, hands, and sometimes other areas (Yang et al., 2004) . A related disorder, paroxysmal extreme pain disorder (PEPD), is characterized by pain and flushing in the submandibular, ocular, and rectal areas (Fertleman et al., 2006; Fertleman et al., 2007) . On the opposite end of the pain spectrum is congenital insensitivity to pain (CIP), also termed channelopathy-associated insensitivity to pain (Cox et al., 2006) . Though not an episodic disorder, CIP results in the complete loss of pain sensation concomitant with neuropathy. While this may at first seem somewhat appealing, individuals with this disorder commonly (and unknowingly) suffer broken bones and tend to accrue injuries to their lips and tongue due to frequent, inadvertent biting during youth. Brain There are a variety of episodic disorders of the brain caused by channel mutations. These can be broadly broken into three categories: paroxysmal movement disorders, epilepsies, and headache disorders. Paroxysmal movement disorders are exemplified by the episodic ataxias and paroxysmal dyskinesias, each with several distinct subtypes. Inherited episodic ataxias are rare, autosomal-dominant disorders of cerebellar motor coordination (Jen et al., 2007) . The various subtypes are distinguished to some extent by clinical differences (e.g., duration of ataxic bouts and the presence or absence of associated symptoms such as myokymia or visual disturbances) and by their genetic cause (gene mutation and/or genetic localization). Episodic ataxia type 2 (EA2) is also genetically and clinically overlapping with spinocerebellar ataxia type 6 (SCA6) and genetically, but only rarely clinically, overlapping with familial hemiplegic migraine type 1 (see below). Paroxysmal dyskinesias are typified by bouts of involuntary movement (Mü ller, 2009) . Specific paroxysmal dyskinesias are distinguished by both their underlying genetics and their symptoms and triggers. Paroxysmal nonkinesigenic dyskinesia, for instance, presents as occasional attacks of dystonia, chorea, or athetosis that can be precipitated by stress or ingestion of coffee or alcohol (Lee et al., 2004) .
Epilepsies are themselves a very broad category of episodic neurologic disorders that can arise from many causes, including metabolic brain disorders, abnormalities of cortical development, brain trauma, or structural lesions of the brain, such as brain tumors. The idiopathic epilepsies are defined as those with apparently normal brain (by imaging) and for which no other cause is recognized. Some of these are heritable and include generalized epilepsy with febrile seizures plus related disorders (GEFS+), autosomal-dominant nocturnal frontal lobe epilepsy (ADNFLE), benign febrile neonatal convulsions (BFNC), and generalized epilepsy with paroxysmal dyskinesia (GEPD). Not surprisingly, these have also been shown to be channelopathies.
GEFS+ is a syndromic disorder and encompasses severe myoclonic epilepsy of infancy (SMEI), borderline SMEI, and intractable epilepsy of childhood (Hirose et al., 2005; Nakayama, 2009) . Seizures in GEFS+-afflicted individuals can vary widely, including afebrile tonic-clonic, absence, and myoclonic types. SMEI is genetically related to GEFS+, but its presentation in patients is much more severe and it results in developmental delay. ADNFLE is a rare epilepsy disorder characterized by complex motor seizures during sleep, often including vocalizations. GEPD is a hybrid of epilepsy and paroxysmal dyskinesia, wherein patients have tonic-clonic or absence seizures as well as signs of paroxysmal dyskinesia (Du et al., 2005) .
While many types of migraine have genetic components, familial hemiplegic migraine (FHM) is one of the few with a simple autosomal-dominant mode of inheritance. FHM is characterized by bouts of migraine with aura associated with hemiparesis and, in some cases, cerebellar degeneration. The subtypes of FHM can be distinguished by both their underlying genetic mechanism and, in a few rare cases, the presence of cerebellar dysfunction (Pietrobon, 2010) . Heart There are numerous types of inherited cardiac arrhythmias caused by ion channel mutations (Campuzano et al., 2010) . These include atrial fibrillations and at least a dozen types of long QT (LQT) syndrome. Elongation of the QT interval results in ventricular tachyarrhythmia and can lead to sudden death.
While the channelopathies presented so far have affected a single organ system, this is not always the case. The clinical manifestation of Andersen-Tawil syndrome (ATS) is broad, containing cranial, facial, cardiac, skeletal muscle, and neurocognitive symptoms (Plaster et al., 2001; Tristani-Firouzi and Etheridge, 2010; Yoon et al., 2006a; Yoon et al., 2006b ). The most striking dysmorphic features are widespread eyes, cleft palate, and syndactyly of the toes. ATS patients also have intermittent bouts of weakness or paralysis like those seen in the other familial periodic paralyses. ATS is also a subtype of LQT syndrome, mentioned above. Determination of its genetic cause has led to the supposition that ATS may also have neurological symptoms. Recent studies have, indeed, found neurological symptoms such as deficits in executive function and abstract reasoning (Yoon et al., 2006a) . Like ATS, Jervell and LangeNielson syndrome (J-LN) is also a multisystem channelopathy and is a LQT syndrome variant. J-LN patients have cardiac arrhythmia concomitant with deafness rather than skeletal muscular or other developmental disorders (Schwartz et al., 2006) . Another interesting multisystem channelopathy, Timothy syndrome, is further discussed below (Splawski et al., 2004 
Review
Normal Interictal Periods and Triggers One of the unusual aspects of many channelopathies is their paroxysmal nature. These patients often appear completely normal between attacks because of homeostatic mechanisms regulating membrane excitability. A common precipitant for all of the episodic disorders presented here is stress of some form. For some channelopathies, such as the periodic paralyses, rest after exercise or fasting can provoke attacks. For others, warm temperatures (erythermelalgia), consumption of certain foods that raise or lower serum potassium (periodic paralyses), or drinking caffeine or alcohol (paroxysmal nonkinesigenic dyskinesia) can precipitate attacks.
When considering how episodic disorders are triggered, it can be helpful to consider the episodic phenotype as one or more stable states separated by a barrier (Figure 1 ). In this model, the stressor serves to propel the current state over the instability barrier into an aberrant state. For some disorders, this aberrant stable state exists in even normal individuals (Jurkat-Rott et al., 2009 ). An example of this would be migraine, where sufficient provocation seems to be able to trigger a migraine in otherwise normal individuals. For other disorders, such as thyrotoxic hypokalemic periodic paralysis (TPP), the mutations may instead be increasing the stability of a normally unstable aberrant state rather than increasing the propensity of triggers to alter the state (Ryan et al., 2010) . Other possibilities include altering the stability of the normal state or some combination of these alterations. Formal dynamical analysis of episodic disorders like that suggested here has, in fact, proven helpful in understanding their pathophysiology (Cannon et al., 1993) and may aid in developing useful therapies. In brief, homeostatic mechanisms are normally able to maintain neurotransmission and both cellular and network excitability within normal limits. Alteration of ion channels decreases the safety margins, thus stressing homeostatic mechanisms such that a normally innocuous stimulus proves pathogenic.
An interesting aspect of channelopathies is that they tend to present clinically in childhood and worsen with maturation, followed by amelioration with further aging. In some cases this seems to be due to differences in splice-form expression during development, such as with erythermelalgia (Choi et al., 2010) . In other cases, this is likely due to hormonal changes, though the exact mechanisms are largely unclear. The best-known example of the affect of hormones on an episodic disorder would be the increased incidence of migraines during menses (Martin and Lipton, 2008) . Another strong example of the influence of hormones on an episodic disorder is TPP, in which treatment of the underlying thyrotoxicosis is sufficient to prevent attacks of episodic weakness. Furthermore, attacks can either increase, as seen in PMC in at least one patient (de Silva et al., 1990) , or decrease, as seen in some hyperKPP patients (Finsterer, 2009) , with pregnancy. Hormones may also help to explain the gender disparities seen in the prevalence of some episodic disorders. The exact manner in which hormones influence episodic disorders remains to be elucidated.
Ion Channels in Multiprotein Complexes
Ion channels serve as the basis by which ions traverse cell membranes to elicit electrical excitability (Hille, 2001 ). They accomplish this task by forming ion-selective pores through the membrane. Ion channels are highly conserved across all living species and may be broadly divided into three categories: voltage-gated, ligand-gated, and others (such as inwardly rectifying potassium channels).
Of the voltage-gated channels, the sodium, calcium, and potassium channel families have received the most study. The voltagegated potassium (K V ) channels are a large family of proteins composed of six transmembrane a helices (S1-S6), with S4 serving as the voltage sensor and a pore-forming loop between S5 and S6 ( Figure 2) . A functional potassium channel is composed of four such subunits, in which each subunit need not be identical, termed heteromultimerization (Gutman et al., 2005) . Sodium (Na V ) and calcium (Ca V ) channels are structurally similar, with the exception that a single transcript contains four internally homologous domains, each equivalent to a voltage-gated potassium channel subunit (Figure 2 ) (Catterall et al., 2005a; Catterall et al., 2005b) . Not surprisingly, each type of channel also has auxiliary subunits that function to modify trafficking, localization, and/or physiologic properties. Chloride channels are structurally distinct, and one has recently been crystallized (Dutzler et al., 2003) . A functional chloride channel is composed of two subunits, which can gate either together or independently (Duran et al., 2010) .
Sodium channels can be generally thought of as generating the upstroke of the action potential. Voltage-gated potassium channels, on the other hand, are largely responsible for repolarizing the membrane and halting an action potential. Calcium channels often do not contribute greatly to action potential generation and propagation but, instead, bridge cellular excitability with intracellular signaling and are vital for excitation-contraction coupling and synaptic release. Chloride channels, finally, often function to set baseline excitability by acting as a current shunt. Sodium Channel Disorders Gating describes the voltage or other properties that affect the activation, deactivation, and inactivation of channels. A common Episodic-disease-related mutations result in one of two possible alterations. They can change the relative stability of the normal and one or more aberrant states. The equilibrium between the two states is then shifted toward the aberrant state. Alternatively, they may result in the increased ability of a stressor to move the system from the normal to an aberrant state. An example of this would be some TPP mutations, which result in altered physiology only during thyrotoxicosis (Ryan et al., 2010) .
feature of many channelopathies, particularly those affecting sodium channels, is alteration of the gating kinetics to produce aberrantly large currents. In hyperKPP, some mutations in the Na V 1.4 sodium channel (e.g., L689I) result in activation at more hyperpolarized potentials coupled with slowed inactivation. The addition of this noninactivating current results in mutant channels not slowly depolarizing the membrane but, rather, rapidly depolarizing it such that action potential initiation is blocked (Bendahhou et al., 2002) . Interestingly, mutations in the same channel can also lead to PMC and PAM, demonstrating that the exact nature and magnitude of alteration due to an individual mutation can lead to quite different clinical phenotypes. A similar case is seen with mutations leading to either CIP or PEPD (Cox et al., 2006; Fertleman et al., 2006) . Both of these are caused by mutations in Na V 1.7, which is expressed in nociceptive dorsal root ganglion and sympathetic ganglion neurons. Loss of function of Na V 1.7 leads to an inability to form action potentials and, therefore, loss of pain sensation. Gain-of-function mutations, on the other hand, result in increased action potential duration and therefore more synaptic transmission, causing heightened pain perception and PEPD. Shifting the gating profile of this channel so that it activates at more hyperpolarized potentials, thereby relaying normally nonpainful inputs as painful, results in erythermelalgia (Dib-Hajj et al., Yang et al., 2004) . Interestingly, this result is only the case in dorsal root ganglion (DRG) neurons. Na V 1.7 is also expressed in sympathetic ganglion neurons, where at least the L858H mutation instead leads to hypoexcitability rather than the hyperexcitability seen with the same mutation in DRG neurons, better explaining the sympathetic symptoms of this disorder (Rush et al., 2006) . These disparate results are due to the presence of Na V 1.8 in DRG neurons. Alterations of gating are also observed in Na V 1.1 mutations leading to type 3 FHM. Here, some mutations result in altered fast and slow inactivation, which, when combined with promigraine conditions, seems to lead to self-limiting hyperexcitability (Cestè le et al., 2008) . Mutations in Na V 1.1 do not only cause migraine; they can also cause a number of epilepsy disorders, such as GEFS+ and SMEI, as mentioned above . The understanding of GEFS+ by the study of mutant Na V 1.1 expressed in nonneuronal cells has been complicated by the fact that there is no theme to the results, with some mutations apparently resulting in a gain of function and others in a loss of function. The creation of mouse models has helped to clarify these results. The R1648H mutation, for example, results in altered kinetics in both excitatory and inhibitory neurons, but these effects seem to be sufficient only in leading to aberrant function in the GABAergic interneurons, which then have reduced excitability (Martin et al., Voltage-gated potassium (K V ) channels are composed of four subunits. Each subunit is composed of six transmembrane segments (S1-S6) and intracellular N and C termini. The ion-conducting pore of the channel is formed by S5 and S6 of the four subunits, the ion selectivity filter by the S5-S6 loop. S4 functions as the voltage sensor. Inward-rectifier potassium (Kir) channels are similar but lack the first four transmembrane segments. Voltage-gated sodium (Na V ) and calcium (Ca V ) channels are, in essence, four tandem repeats of a voltage-gated potassium channel. Because of their tetramerization, potassium channels can have dominant-negative mutations. Under each channel name is an abbreviated list of human neurological disorders resulting from mutations in such channel genes.
2010; Tang et al., 2009) . SMEI mutations in Na V 1.1 are quite severe and generally lead to a complete loss of channel function.
As loss of sodium current should lead to hypoexcitability, it was not at first apparent why this would lead to severe epilepsy. Mouse models lacking Na V 1.1 indicated that GABAergic interneurons are preferentially affected by loss of Na V 1.1, while excitatory neurons are spared. It seems, then, that like GEFS+, SMEI mutations result in decreased GABAergic interneuron activity (Yu et al., 2006) . Patients with SMEI also have nonepileptic phenotypes, such as ataxia. Na V 1.1 is also present in Purkinje cells, though it is not the only sodium channel expressed there. While SMEI mutations do not alter the threshold for action potential formation, they do alter some characteristics of the sodium current and lead to altered firing rate. These alterations in GABAergic output may be sufficient to account for cerebellumassociated comorbidities and predict that the other SMEI comorbidities may be caused by similar mechanisms (Kalume et al., 2007) . While most gain-of-function mutations alter gating, some result in quite novel properties. The mutations in both Na V 1.4 and Ca V 1.1 underlying hypoKPP are present in the voltagesensing S4 helix (Jurkat-Rott et al., 2009; Sokolov et al., 2007) . These mutations result in the creation of an alternate ion-conducting pore through the S4 slide helix, termed a gating pore current. For the Na V 1.4 mutations, this current seems to conduct protons or sodium, depending on the mutation; the fact that Ca V 1.1 does not express well in a heterologous system has made its mutations more difficult to study, though some insights have recently been gained (Jurkat-Rott et al., 2009) . In these disorders, a cation leak in the presence of hypokalemia results in the shift of the resting membrane potential to a more depolarized second stable state, termed paradoxical depolarization. Direct leakage of sodium seems to cause intracellular accumulation and direct alteration of the resting membrane potential, while leakage of H + indirectly results in accumulation of intracellular sodium ions by activation of the Na + /H + exchanger (Catterall, 2010) . Not surprisingly, then, the amplitude of the gating pore current inversely correlates with the severity of hypokalemia required to elicit an attack.
Calcium Channel Disorders
As with sodium channels, mutations of calcium channels can be either gain-or loss-of-function alleles. Mutation of Ca V 2.1, the P/Q-type channel expressed throughout the brain, can result in FHM type 1 (FHM1), EA type 2 (EA2), spinocerebellar ataxia type 6 (SCA6), or a mixture of the three. FHM1 mutations lead to alteration of Ca V 2.1 kinetics such that channels depolarize at more hyperpolarized potentials than normal (e.g., R192Q) (Hans et al., 1999) . Recent mouse models have indicated that these Ca V 2.1 mutations in FHM1 lead to enhanced excitatory, but not inhibitory, synaptic transmission and increase the propensity for cortical spreading depression (Pietrobon, 2010; Tottene et al., 2009 ). FHM1 mutations also tend to result in decreased sensitivity to inhibition by G protein-coupled receptors (Melliti et al., 2003; Serra et al., 2009; Weiss et al., 2008) . In general, then, these alterations likely decrease the threshold for inducing cortical spreading depression. EA2 mutations, on the other hand, tend to result in decreased current, often due to protein instability (e.g., G293R) (Wan et al., 2005) . Many are, in fact, splicing or frameshift mutations expected to result in total loss of function. SCA6 mutations primarily result in a toxic gain of function involving CAG repeats in the P-type splice form of the channel (Zhuchenko et al., 1997) . This form is highly expressed in Purkinje cells of the cerebellum, where the mutations cause intracellular aggregates (Ishikawa et al., 1999) . While these channels can be functional, they tend to form intracellular inclusions (Watase et al., 2008) .
Voltage-Gated Potassium Channel Disorders
There are also a number of channelopathies related to the voltagegated potassium channel. Examples include EA1 and benign febrile neonatal convulsions type 1 and 2 (BFNC1 and BFNC2). As potassium channels are vital in the downstroke of the action potential, it is not surprising that mutations might cause prolonged action potentials and altered excitability of different neuronal populations. In EA1, K V 1.1 mutations lead to a drastic decrease in currents, often at least partly due to improper trafficking. Mutations such as V174F also result in activation at more depolarized potentials, further compounding the effect (Browne et al., 1994; Zerr et al., 1998) . These defects in gating can also have a dominant-negative effect on coexpressed wild-type subunits (Zerr et al., 1998) . K V 1.1 is expressed in interneurons of the cerebellum that alter Purkinje firing and cerebellum output. In contrast, mutations in K V 7.2 and K V 7.3 that cause BFNC1 and BFNC2 seem to result in haploinsufficiency (Biervert et al., 1998; Lerche et al., 1999; Schroeder et al., 1998; Singh et al., 1998) .
Chloride Channel Disorders
The chloride reversal potential in skeletal muscle plays a vital role in setting the resting membrane potential. Not surprisingly, then, drastic decrease in chloride permeability results in increased membrane resistance, such that a given depolarizing input is able to depolarize a greater surface area of membrane, and altered resting membrane potential. For myotonia congenita to occur, a large portion (90%) of chloride conductance must be blocked (Furman and Barchi, 1978) . Mutations in the skeletal muscle chloride channel, ClC-1, can result in either a dominant (Thomsen disease) or a recessive (Becker generalized myotonia) form of myotonia congenita. These mutations tend to produce either purely nonfunctional channels or channels that open at a more depolarized potential such that the chloride conductance is no longer able to compensate for depolarization caused by potassium accumulation in the T-tubular system of skeletal muscle, thus resulting in hyperexcitability (Duran et al., 2010) . Inward Rectifier Potassium Channel Disorders Inward rectifier potassium (Kir) channels are a broadly expressed family of 18 members (Kubo et al., 2005; Ryan et al., 2010) . Each of the four subunits of a functional channel is composed of two transmembrane a helices (evolutionarily related to the S5 and S6 transmembrane helices of voltage-gated potassium channels) and intracellular N and C termini (Figure 2 ). Like voltagegated channels, Kir channels can heteromultimerize. It is interesting that to date, there are few neurologic disorders associated with Kir channel mutations in humans. The best studied is ATS, which is due to mutations in Kir2.1. The Kir2 family (Kir2.1-Kir2.6), with the exception of Kir2.5, is a class of strong inward rectifiers, meaning that channels can pass more current into than out of a cell. Kir2.1 is particularly widely expressed; it is found in the heart, brain, and skeletal muscle, among other regions. There are a large number of mutations in Kir2.1, and they alter its function in a variety of ways (Donaldson et al., 2004) . Some alter the ability of the channel to bind to PIP 2 in the membrane, which is required for channel opening. Others result in haploinsufficiency or loss of function in a dominant-negative manner through a variety of other mechanisms. In the heart, Kir2.1 contributes significantly to the I k1 current, which is responsible, in part, for repolarization following the upstroke of an action potential. ATS mutations lead to prolongation of the cardiac action potential and thereby lead to arrhythmias. ATS mutations likely lead to the observed periodic paralytic phenotype by decreasing the clearance of potassium in the T-tubular system.
Timothy syndrome is another channelopathy affecting more than one organ system. The causative gene encodes Ca V 1.2, which is expressed in the heart but also in other tissues, including the brain. These patients manifest multiorgan dysfunction, including lethal arrhythmias, syndactyly, immune deficiency, congenital heart disease, intermittent hypoglycemia, cognitive abnormalities, and autism (Splawski et al., 2004) . It is interesting that ATS and Timothy syndrome have overlapping features, including cardiac arrhythmias, limb dysmorphisms, and CNS features. In all patients characterized to date, Timothy syndrome results from a de novo mutation in Ca V 1.2 (G406R and G402S) (Splawski et al., 2005; Splawski et al., 2004) . Interestingly, mutations in the alternatively spliced exon 8 lead to type 2 Timothy syndrome, which differs from the classical variant by being primarily cardiac due to the preferential expression of this splice form in the heart (Splawski et al., 2005) .
A recently discovered disorder, alternately named SeSAME syndrome (seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance) and EAST syndrome (the presence of epilepsy, ataxia, sensorineural deafness, tubulopathy), is characterized by similar loss-of-function mutations in Kir4.1 (Bockenhauer et al., 2009; Scholl et al., 2009) . These mutations cause a disorder characterized by salt wasting, epilepsy, ataxia, and sensorineural deafness. These mutations all lead to channels that are unable to pass current in the physiologically relevant pH range (Reichold et al., 2010) . Ligand-Gated Ion Channel Disorders Episodic disorders due to mutation of ligand-gated channels are relatively rare. Examples include ADNFLE and a congenital myasthenic syndrome, due to mutations in nicotinic acetylcholine receptors (nAChRs), and hyperekplexia, due to mutation in a glycine receptor (GlyR). A likely reason for this paucity is that the mutations in such widely expressed proteins may prove lethal. Both nAChRs and GlyRs are pentameric in structure, with five subunits asymmetrically surrounding a central pore (Albuquerque et al., 2009; Lynch, 2004) . The exact composition of subunits in an nAChR can significantly alter the receptor's biochemical and biophysical properties. Mutations in CHRNA2, CHRNA4, and CHRNB2 can result in ADNFLE. There have been many contradictory studies involving these mutations, but a common theme is that ADNFLE mutations seem to cause a gain of function whereby nAChRs are more sensitive to activation by acetylcholine (Marini and Guerrini, 2007) . Mutations in a variety of pre-through postsynaptic neuromuscular junction proteins, including many nAChR subunits, can also result in congenital myasthenic syndrome (Engel et al., 2010) . These mutations can broadly result in three alterations. First, they can reduce expression, thereby degrading the fidelity of signal transmission. Second, mutations can lead to a slowing of the decay of nAChR currents, for example by altering the open or closed state kinetics or the Ach dissociation time constant. These prolonged openings then seem to lead to overloading of the postsynaptic region of the endplate and to weakness. The third broad set of alterations result in abnormally fast decay of nAChR currents and result in the disorder as with mutations altering expression.
Mutations in a variety of GlyR subunits can result in hyperekplexia, characterized by an exaggerated startle response and generalized weakness (Harvey et al., 2008; Lynch, 2004) . Mutations generally decrease the inhibitory input from GlyR, leading to excessive excitation.
General Themes of Channelopathies
General themes from these findings include the exact expression profile of a protein dictating the clinical phenotype of its mutations. Most channelopathies affect only one organ system because the associated protein is not expressed broadly. Channelopathies resulting from mutations in genes that are more widely expressed are apparently less common, most likely because they would be predicted to cause more severe or lethal disorders. This general theme becomes more complicated in the brain, where mutated channels may have opposite effects on different neuronal populations, as exemplified by the Na V 1.7 mutations in erythermelalgia. Furthermore, the exact role that the protein plays in action potential formation and information transfer (e.g., synaptic transmission) can largely predict the result of underlying mutations, which tend to produce prolonged action potentials. Thus, most sodium channel mutations result in aberrantly large sodium currents during depolarization or when there would otherwise be no significant sodium current. Chloride and potassium channels, on the other hand, tend to have mutations that result in a loss of function, often in a dominant-negative manner. Calcium channels tend to have mutations that alter synaptic transmission. Whether the resulting increased action potential duration results in eventual hypo-or hyperexcitability is largely dependent on the severity of the alteration, with more pronounced depolarizations resulting in hypoexcitability due to inactivation of wild-type voltage-gated channels. In the brain, it is the degree to which mutations affect excitatory or inhibitory neurons that predicts whether a mutation results in aberrant network hypo-or hyperexcitability.
Not All Episodic Neurological Disorders Are Due to Ion Channel Mutations
All electrical disorders must ultimately result from altered channel or membrane physiology, and mutations in ion channels are one way of leading to such diseases. But an interesting new direction of research on episodic disorders focuses not directly on ion channels but on the structural proteins that control their surface localization, targeting, and function. The canonical example of this is LQT syndrome type 4, of which mutations of the ubiquitously expressed Ankyrin-B are one cause (Hashemi et al., 2009) . Splice forms of Ankyrin-B result in proteins with different subcellular distributions. Many of the Ankyrin-B mutations result in a simple loss of function, whereas others seem Neuron 68, October 21, 2010 ª2010 Elsevier Inc. 287 Neuron Review to have a dominant-negative effect. These mutations result in varying degrees of mislocalization and altered expression of ion channels and transporters, such as the Na/K ATPase and the Na/Ca exchanger (Hashemi et al., 2009) . These mutations indicate the importance of subcellular localization in maintaining normal function.
While many familial episodic neurological disorders are due to mutations in either ion channels or structural proteins that affect them, there is also emerging interest in proteins that seem to more indirectly lead to episodic phenotypes. Examples of such disorders are the audiogenic seizure (AGS)-susceptible phenotype of the Frings mouse and familial febrile seizures, autosomal-dominant lateral temporal epilepsy (ADLTE) and paroxysmal nonkinesigenic dyskinesia (PNKD) in humans. Presentation of a loud acoustic stimulus to a Frings mouse induces a seizure phenotype including wild running followed by tonic flexion and then tonic extension (Skradski et al., 2001 ). This phenotype is not caused by an ion channel mutation, as originally surmised, but by a mutation in a very large orphan G protein-coupled receptor alternately called Mass1 and Vlgr1. This same protein is also mutated in some cases of familial febrile seizures (Nakayama et al., 2002) . Interestingly, both the mouse and the human phenotypes are caused by early truncation of the protein. The immense size of Mass1 has made its study difficult; how mutations in it lead to either of these phenotypes remains an open question, though presumably its activation modulates neuronal ion channels.
Another episodic neurological disorder reminiscent of a channelopathy is ADLTE, which is caused by mutations in LGI1 in around 50% of cases (Nobile et al., 2009) . ADLTE is characterized by partial seizures with auditory hallucinations. LGI1 functions by interacting with the postsynaptic ADAM22 protein and the presynaptic K V 1 potassium channels (Fukata et al., 2010) .
LGI1 can alter K V 1 inactivation. The normal function of LGI1 seems to be to tune synaptic transmission, which is presumably altered by ADLTE mutations.
PNKD is caused by mutations in a gene called Pnkd, whose function is currently unknown (Lee et al., 2004) . Interestingly, the protein encoded by Pnkd is novel but shares homology with a family of enzymes important in stress-response pathways. These disorders open up new routes for the exploration of new pathways that alter channel activity and synaptic release, which might also prove useful in devising new treatments for other neurologic disorders.
Ion Channel SNPs Can Be Disease Related
Understanding of the genetic etiology of neurological disorders has led to an increased understanding of normal human variability, such as pain perception. As discussed above, mutations in SCN9A can result in either extreme or complete loss of pain perception. This led to the hypothesis that SNPs in SCN9A might lead to nonpathological differences in pain perception (Reimann et al., 2010) . Genotyping of numerous individuals with various pain threshold scores indicated that those with a particular SNP (A allele at SNP rs6746030) have increased pain scores to a given noxious stimulus. Another recent example of such findings is the relation of SNPs in CACNG2 with chronic pain susceptibility. CACNG2 encodes Stargazin, which is involved in regulating AMPA receptor trafficking and modulation. A number of SNPs in this gene have been shown to be associated with increased risk of postmastectomy chronic pain (Nissenbaum et al., 2010) . While these results have not been further validated and the SNPs have not been characterized, they presumably lead to altered plasticity following nerve injury.
Similar to this, study of the familial channelopathies has led to the discovery of new risk alleles. Mutations in SCN5A lead to a variety of cardiac arrhythmia disorders. As with pain perception, above, this led to the theory that common SNPs in SCN5A may be associated with risk for cardiac arrhythmia (Splawski et al., 2002) . Indeed, common SNPs in SCN5A are associated with an increased risk of arrhythmia. The Y1102 variant, for example, is a common allele in the African American population and is significantly enriched in individuals with cardiac arrhythmia. This polymorphism results in slightly increased channel activation at more hyperpolarized potentials. When combined with nongenetic risk factors, such mild modifications seem to be sufficient to lead to significantly increased rates of disease.
Study of Familial Channelopathies Helps in Understanding Sporadic Channelopathies
While understanding of the genetics of familial episodic neurological disorders can help explain normal human variation (e.g., SCN9A SNPs and pain perception) and risk susceptibility (e.g., SCN5A and cardiac arrhythmia) and predict less apparent clinical phenotypes (e.g., the expansion of the ATS phenotype predicted by the expression profile of Kir2.1), it can also serve as the basis for probing sporadic episodic neurological disorders. A recent example of this is thyrotoxic hypokalemic periodic paralysis (TPP). TPP is clinically similar to hypoKPP but is concomitant with thyrotoxicosis of any cause, treatment of which blocks further attacks. Study of TPP has been hampered by the fact that it is typically sporadic. Given the extensive knowledge of the genetics and physiology of the familial periodic paralyses and the striking clinical similarity between them and TPP, it was hypothesized that TPP might also be a channelopathy. Consequently, many skeletal muscle ion channel genes, whose promoter regions harbored consensus sequences for regulation by thyroid hormone, were screened for mutations. The Kir2.6 ion channel was serendipitously found in this process, and mutations were found in many cases of TPP (Ryan et al., 2010) . Kir2.6 is interesting in that it demonstrates many of the general themes of familial channelopathies. First, stress in the form of thyrotoxicosis and some other triggers, such as carbohydrate loading, precipitate attacks. Our current understanding of the pathophysiology of TPP is much less complete than for the familial periodic paralyses, in part because Kir2.6 was discovered only recently. In addition, in vitro experiments show complex consequences of different mutations. First, Kir2.6 expression is upregulated by thyroid hormones. Second, some of the mutations produce channels having normal kinetics under basal conditions that are altered with increased thyroid hormone. Furthermore, some mutations are predicted to alter subcellular localization, reminiscent of mutations in structural proteins discussed above, while at least one mutation causes a loss of function, as is commonly seen in potassium channel disorders. Knowledge of the familial channelopathies is likely to prove useful in elucidating other such sporadic disorders.
Acquired Channelopathies
Autoimmune Channelopathies Not all channelopathies are genetic in origin. An emerging group, the autoimmune channelopathies, are due to antibodies against ion channels rather than mutations in ion channels or proteins that modify their localization or modulate their function (Lang and Vincent, 2009 ). Examples of these include Lambert-Eaton syndrome and Isaac's syndrome (or neuromyotonia), which are caused by antibodies against voltage-gated calcium and potassium channels, respectively. Lambert-Eaton syndrome is characterized by proximal muscle weakness with areflexia, while neuromyotonia is characterized by abnormal muscle activity that arises from neuronal hyperexcitability. More severe cases of Isaac's syndrome can also involve CNS symptoms such as anxiety and memory loss.
Other examples of acquired channelopathies include autoantibodies raised against either the AMPA receptor subunit GluR3 or the NMDA receptor NR2B subunit in Rasmussen's encephalitis, a severe progressive epilepsy disorder typically arising in childhood and often leading to intellectual deterioration (Granata, 2003; Takahashi et al., 2005) . A number of possible explanations for Rasmussen's encephalitis pathogenesis have been proposed, such as the antibody-binding-induced presentation of an agonistbinding site with concomitant increases in AMPA receptor-mediated current or complement-mediated cytotoxicity (in the case of GluR3). It should be noted that not all cases of Rasmussen's encephalitis are associated with antibodies against GluR3 and that such antibodies are seen in some cases of noninflammatory epilepsy (Mantegazza et al., 2002; Wiendl et al., 2001) . Transcriptional Channelopathies Not all acquired channelopathies are due to the creation of antibodies against ion channels; transcriptional channelopathies result from the aberrant transcription of an otherwise normal gene (Waxman, 2001) . Altered transcription can be due to any cause, with two examples being peripheral nerve injury and multiple sclerosis (MS). Peripheral nerve injury can result in hyperexcitability of the regenerated axon that is due to decreased expression of some sodium channels normally present and increased expression of other sodium channels that are normally silent. In dorsal root ganglion neurons, for example, Na V 1.8 and Na V 1.9 are normally highly expressed (Waxman, 2001 ), whereas Na V 1.3 becomes the predominant form following axonal transection. These Na V 1.3 channels recover more quickly from inactivation and lead to hyperexcitability. The most profound alteration in MS is neuronal demyelination. In the TAIEP rat model of MS, for example, myelin degeneration in the cerebellum results in increased expression of Na V 1.8 in this tissue. While this may in large part compensate for the loss of myelin, Na V 1.8 channels are slow to enter the inactive state and recover from this state relatively quickly, suggesting that their increased expression in Purkinje cells might lead to ataxia. In humans with MS, motor axons in the median nerve show increased slow K+ current, which is most readily explained by increased transcription of the underlying current (Ng et al., 2008) .
Conclusions
There are a wide variety of episodic neurological disorders, many of which are due to mutations in ion channels or proteins that modify their localization. Channelopathies result from a wide array of mutations, but they all result in a single consistent theme: an increased ability to move normal cellular and/or network excitability into a parallel aberrant excitability state (Figure 1 ). While this state sometimes exists at a somewhat stable level without the presence of an underlying mutation (e.g., cortical spreading depression can be evoked in even wild-type mice given sufficient KCl administration), these mutations seem to result in either the aberrant state becoming more stable relative to the normal state or the barrier to transitions from normal to aberrant states being reduced. Homeostatic mechanisms, then, are no longer capable of keeping the system within normal parameters when stressed by a precipitant. Developing new therapies targeting the transition into an aberrant state rather than the specific mutated protein may prove useful.
In the channelopathies, mutations tend to lead to an increase in action potential duration. Often this leads to simple hyperexcitability, with the resulting phenotype dependent on the expression pattern of the underlying mutated protein. Consequently, such mutations in muscle lead to myotonia, while mutations in proteins from neurons involved in nociception result in increased pain sensation. In the brain, it is a channel's effects on the various subtypes of neurons in a network that predict the resulting alteration of network dynamics. Further alteration by the addition of persistent currents results in even more depolarization and an inability to reach threshold due to inactivation of wild-type voltage-gated channels. Understanding these mechanisms may prove useful in devising novel treatments, as selectively targeting the mutated protein often proves difficult and other proteins in the system may be more structurally unique.
Study of these familial variants is also helpful in elucidating sporadic channelopathies such as TPP and the acquired channelopathies. Having already formed much of the framework for understanding a physiological alteration, we are better able both to predict the underlying pathophysiological cause and to devise useful therapeutic strategies.
Important future directions in the field will be to elucidate how precipitants result in the clinical phenotype. For some disorders, such as hypokalemia triggering hypoKPP, this process is becoming clearer, but this is not generally the case. It is also not always clear how hormones interact with channelopathies to alter the severity and prevalence. Thyrotoxicosis, for example, is much more common among women than men, but TPP is much more prevalent among men than women. Understanding these interplays will prove important in fully understanding the pathogenic mechanisms of the disease. Studies of mouse models will be invaluable in these studies and will also serve to increase our knowledge of normal physiology. Some diseases, such as TPP, are not readily amenable to study by the creation of an animal model. Instead, study of primary human tissue and the use of computational models may be helpful.
For patients, the benefits from these studies will be multifold. The discovery of underlying genetic causes aids in proper diagnosis, and therefore proper treatment, of diseases that can be clinically quite similar. Future studies will likely find SNPs in these genes associated with disease risk. While many such associations prove spurious, the linkage of these genes with known familial disorders greatly increases the prior probability of such findings. The ability to reduce genetic heterogeneity during enrollment into clinical trials should result in both more significant scientific results and treatments that are better targeted toward more genetically homogeneous subgroups of patients. Finally, as genes encoding proteins that are not ion channels are now being shown to cause some episodic disorders, new pathways and targets for drug development are being identified.
